Ansa Biotechnologies to Showcase Early Access Customer Success at Upcoming Global Synthetic Biology Conference
30 Abril 2024 - 7:03AM
Business Wire
Several prominent scientists will share
insights gained from ability to synthesize complex DNA sequences
that were previously impossible with legacy technologies
Ansa Biotechnologies, Inc., the trusted partner for complex DNA
synthesis, today announced its speaker lineup for presentations at
the upcoming Global Synthetic Biology (SynBioBeta) Conference in
San Jose, Calif., from May 6-9, 2024. The company is also expanding
its early access program for complex DNA synthesis. Meeting
attendees will be able to learn how to participate in the program
throughout the conference in booth #312.
Featured Presentations
From Complexity to Commercialization: The DNA Synthesis Saga
Continues Main Stage on Tuesday, May 7, 9:10 am PDT Featured panel
participant: Jason T. Gammack, CEO of Ansa Biotechnologies
Expand Your Design Space: Ask Bigger Questions with Complex DNA
Synthesis Main Stage on Tuesday, May 7, 12:05 pm PDT Jason T.
Gammack
Embrace Complexity: Insights from the Cutting Edge of Enzymatic
DNA Synthesis Breakout session on Tuesday, May 7, 2:45 pm PDT
- Olga Bielska, PhD, Buck Institute for Research on Aging
- Greg Lohman, PhD, New England Biolabs
- Tae Seok Moon, PhD, Engineering Biology Research
Consortium
- Jaymin Patel, PhD, University of California, Berkeley
Ansa’s synthesis services are based on its proprietary
technology, which enables ultra-rapid production of complex DNA
sequences that can be difficult or even impossible to produce with
legacy synthesis techniques. The enzymatic approach eliminates the
need for harsh chemicals and does not damage the growing DNA
molecule as it is made, which allows for the direct and accurate
synthesis of sequences that can be hundreds, and potentially
thousands, of bases long. Customers around the world are now taking
advantage of these services to develop critical advancements in
therapeutics, vaccines, biomanufacturing, agriculture, and
more.
“Ansa is enabling a new wave of innovation in healthcare and
life science research,” said Mr. Gammack. “We are looking forward
to meeting with the SynBioBeta attendees, sharing some of our early
access success stories, and learning more about how we can help
members of this community push the limits of their research by
delivering complex DNA sequences for their most ambitious
projects.”
Ansa is now building on the success of its limited early access
program and increasing availability to its complex DNA synthesis
services. The program offers DNA sequences in both sequence-perfect
clonal DNA or faster sequence-verified linear dsDNA fragment
formats. To learn more about how to participate in the expanded
early access program, visit ansabio.com/early-access.
About Ansa Biotechnologies
Ansa Biotechnologies is enabling customers to push the limits of
their scientific projects by delivering DNA sequences that can be
difficult or even impossible to produce with legacy synthesis
techniques. Ansa’s unique services feature the company’s
proprietary synthesis technology, which enables ultra-rapid
enzymatic production of complex DNA sequences. This novel approach
is poised to accelerate innovation across healthcare, life science
research, and other industries powered by synthetic DNA. Ansa is
headquartered in Emeryville, CA. For more information, visit
ansabio.com or follow on X and LinkedIn.
Ansa Biotechnologies and the Ansa Biotechnologies logo are
trademarks of Ansa Biotechnologies, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240430607044/en/
Andrew Noble (415) 722-2129 andrew@bioscribe.com